Is SBRT Boost Feasible for PET Positive Lymph Nodes for Cervical Cancer? Evaluation using Tumor Control Probability and QUANTEC Criteria

医学 宫颈癌 核医学 颈淋巴结 淋巴 放射科 医学物理学 癌症 内科学 病理 转移
作者
J. E. Snyder,A. Willett,Wenqing Sun,Yusung Kim
出处
期刊:Practical radiation oncology [Elsevier BV]
卷期号:9 (2): e156-e163 被引量:5
标识
DOI:10.1016/j.prro.2018.10.012
摘要

This study aimed to examine the feasibility of stereotactic body radiation therapy (SBRT) as an external beam radiation therapy boost to positron emission tomography (PET) positive lymph nodes (LN) in patients with cervical cancer and to evaluate overall tumor control probability (TCP) increase.Ten patients with cervical cancer and PET positive LN metastasis who received external beam radiation therapy (45 Gy), followed by a 3-dimensional conformal radiation therapy boost (5.4-9 Gy) and tandem-and-ovoid high-dose-rate brachytherapy (16-30 Gy) were retrospectively enrolled in this study. SBRT plans were generated using 21 Gy, 24 Gy, or 30 Gy as a replacement for 3-dimensional conformal radiation therapy boost. The 2 Gy-per-fraction equivalent dose maps were made using an α/β value of 10 for PET positive LNs and 3 for organs at risk (OARs). TCP values were calculated using a logistic TCP model, where 2 input parameters (D50 and Gamma50 = 2) were modeled by 2 clinical outcomes: our institution and the literature. OAR sparing was evaluated using Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC) dose limits.Thirty percent of 10 patients receiving conventional boost experienced recurrence. The TCP of the SBRT schemes was 88% ± 7% (97% ± 2%; 21 Gy), 96% ± 1% (99% ± 0%; 24 Gy), and 99% ± 1% (100% ± 0%; 30 Gy), and the conventional LN-boost TCP value was 25% ± 11% (58% ± 15%) when TCP input parameters were based on published clinical outcome data for LN SBRT treatments (institutional outcome data). The tumor coverage doses (D90) of the SBRT boost plans were on average 32.34 Gyαβ=10 (21 Gy), 37.78 Gyαβ=10 (24 Gy), and 55.54Gyαβ=10 (30 Gy) higher than the conventional LN boost plan. The QUANTEC OAR dose constraints were met for the bladder, rectum, and bowel in all cases for the SBRT LN 21 Gy group, and in 90% and 70% of cases in the SBRT LN 24 Gy and SBRT LN 30 Gy groups, respectively.An SBRT boost dose of 30 Gy can be delivered without compromising QUANTEC OAR limits. The use of SBRT increases TCP values, regardless of the input parameters.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
ccc完成签到 ,获得积分10
10秒前
雪山飞龙发布了新的文献求助10
13秒前
我要看文献完成签到 ,获得积分10
14秒前
16秒前
王吉萍完成签到 ,获得积分10
16秒前
SciGPT应助Bliteper采纳,获得10
17秒前
纯真保温杯完成签到 ,获得积分10
21秒前
wei发布了新的文献求助10
22秒前
呆萌芙蓉完成签到 ,获得积分10
27秒前
大大彬完成签到 ,获得积分10
37秒前
剑过无声完成签到 ,获得积分10
39秒前
pl脆脆完成签到 ,获得积分10
40秒前
鱼鱼和石头完成签到 ,获得积分10
40秒前
单纯的小土豆完成签到 ,获得积分0
40秒前
wei完成签到,获得积分10
45秒前
煎饼果子完成签到 ,获得积分10
45秒前
48秒前
可靠映秋完成签到,获得积分10
50秒前
isedu完成签到,获得积分0
53秒前
55秒前
醒了没醒醒完成签到 ,获得积分10
59秒前
小公牛完成签到 ,获得积分10
1分钟前
黑大侠完成签到 ,获得积分0
1分钟前
Philip完成签到,获得积分10
1分钟前
dada完成签到,获得积分10
1分钟前
Jason完成签到 ,获得积分10
1分钟前
王俊1314完成签到 ,获得积分10
1分钟前
白昼の月完成签到 ,获得积分0
1分钟前
oxear完成签到,获得积分10
1分钟前
kkk完成签到 ,获得积分10
1分钟前
後来完成签到 ,获得积分10
1分钟前
kitsch完成签到 ,获得积分10
1分钟前
韩钰小宝完成签到 ,获得积分10
1分钟前
香丿完成签到 ,获得积分10
1分钟前
燕然都护发布了新的文献求助10
1分钟前
冷静妙海完成签到 ,获得积分10
1分钟前
文献搬运工完成签到 ,获得积分10
2分钟前
苁蓉远志完成签到 ,获得积分10
2分钟前
燕然都护完成签到,获得积分10
2分钟前
卢星彤完成签到 ,获得积分10
2分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
PowerCascade: A Synthetic Dataset for Cascading Failure Analysis in Power Systems 2000
Various Faces of Animal Metaphor in English and Polish 800
The SAGE Dictionary of Qualitative Inquiry 610
Signals, Systems, and Signal Processing 610
On the Dragon Seas, a sailor's adventures in the far east 500
Yangtze Reminiscences. Some Notes And Recollections Of Service With The China Navigation Company Ltd., 1925-1939 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 物理 内科学 复合材料 催化作用 物理化学 光电子学 电极 细胞生物学 基因 无机化学
热门帖子
关注 科研通微信公众号,转发送积分 6344964
求助须知:如何正确求助?哪些是违规求助? 8159582
关于积分的说明 17156893
捐赠科研通 5400892
什么是DOI,文献DOI怎么找? 2860628
邀请新用户注册赠送积分活动 1838504
关于科研通互助平台的介绍 1688030